A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge.

scientific article

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2018NatCo...9.2363M
P6179Dimensions Publication ID1104575301
P356DOI10.1038/S41467-018-04758-9
P2888exact matchhttps://scigraph.springernature.com/pub.10.1038/s41467-018-04758-9
P932PMC publication ID6006336
P698PubMed publication ID29915222

P50authorBarton HaynesQ4865631
Sampa SantraQ88772993
Bhavna HoraQ114512865
Amy M PrinciottoQ125314596
Andrés FinziQ60727346
Joseph SodroskiQ64524473
P2093author name stringM Anthony Moody
Navid Madani
Jonathan Richard
Shilei Ding
Laura Sutherland
Todd Bradley
Bruno Melillo
Amos B Smith Iii
Brandon P Conn
Connie A Zhao
Jérémie Prevost
Linh Mach
P2860cites workThe HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and ImmunogensQ22242262
A humanized antibody that binds to the interleukin 2 receptorQ24600912
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Q24645530
Statistics review 12: survival analysisQ24800418
Nonparametric Estimation from Incomplete ObservationsQ25938997
The neighbor-joining method: a new method for reconstructing phylogenetic treesQ25939010
HIV-Host Interactions: Implications for Vaccine DesignQ26765966
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusQ27644501
Molecular architecture of native HIV-1 gp120 trimersQ27651385
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutininQ27671619
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingQ27675486
Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding SiteQ27681568
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequencesQ27860580
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal OmegaQ27860809
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor bindingQ28646883
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodiesQ29614531
Deciphering key features in protein structures with the new ENDscript serverQ29617219
Immune-correlates analysis of an HIV-1 vaccine efficacy trialQ29617377
Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primatesQ30831495
B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.Q33373664
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.Q44044488
Developing an HIV vaccineQ47852386
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study GroupQ47887130
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.Q53851964
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell lineQ55245697
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMsQ59059475
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Q33647300
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.Q33674461
CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodiesQ33743734
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroQ33853775
HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.Q33887674
Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compoundsQ33964006
Evaluation of survival data and two new rank order statistics arising in its considerationQ34054360
Comparing individual means in the analysis of varianceQ34586410
Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencingQ34742873
Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopesQ34791232
Conformational dynamics of single HIV-1 envelope trimers on the surface of native virionsQ35006601
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionQ35076717
CD4 mimetics sensitize HIV-1-infected cells to ADCC.Q35644696
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef.Q35868046
Envelope Glycoprotein Internalization Protects Human and Simian Immunodeficiency Virus-Infected Cells from Antibody-Dependent Cell-Mediated CytotoxicityQ36086204
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 bindingQ36230268
HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansQ36252656
Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clonesQ36351700
Antigenic conservation and immunogenicity of the HIV coreceptor binding siteQ36403587
Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry InhibitionQ36681727
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.Q36824891
Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic CompoundsQ36878885
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.Q37002237
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infectionQ37033294
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionQ37273158
Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope GlycoproteinsQ37363561
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccinationQ37471315
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic CompoundsQ37593189
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicityQ37644079
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In VivoQ38652858
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.Q38713380
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.Q39457063
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complexQ39878965
BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular CytotoxicityQ40279352
Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allograftsQ42670216
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)2363
P577publication date2018-06-18
P1433published inNature CommunicationsQ573880
P1476titleA CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge.
P478volume9

Reverse relations

cites work (P2860)
Q90286963A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity
Q93105022CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies
Q90262190Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands
Q64231610Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA
Q90287106Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV
Q90412734Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity
Q92327047Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
Q92482128Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer
Q93079833Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells

Search more.